Depomed Inc. granted an exclusive license to Solvay Pharmaceuticals Inc. for North American rights to DM-1796 (formerly Gabapentin GR) in pain indications. The drug - an extended-release version of the active ingredient in Pfizer Inc.'s marketed seizure and pain drug, Neurontin - is in Phase III trials for postherpetic neuralgia (PHN). (BioWorld Today)

Angel investors are well known for helping start-up companies bridge the gap between sweat equity and venture funding. But in the current bear market, later-stage companies, too, are finding that angels just might be the answer to their prayers. (BioWorld Financial Watch)

Executive compensation did not escape the harsh glare of the public spotlight during the recent implosion of the financial service industry. (BioWorld Today)

After selling a building, a marketed product and a subsidiary during the past year, AEterna Zentaris Inc. continued its asset monetization strategy by selling its Cetrotide (cetrorelix) royalties to Cowen Healthcare Royalty Partners LP in exchange for $52.5 million. (BioWorld Today)